Abstract. Increasing evidence suggests that microRNAs are involved in human carcinogenesis as tumor suppressors or oncogenes. A growing number of reports has shown that an interest has been sparked in aberrant microRNA expression and how they can be used to treat human diseases, including cancer. However, their precise biological role remains largely unknown. In the present study, we aimed to identify micro-RNA species involved in the regulation of tumor growth. By performing quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis, we demonstrated that mir-663 was downregulated in human gastric cancer cell lines unlike in normal cells. A transient introduction of mir-663 into the human gastric cancer cell lines BGC823 and SNU5 induced morphology changes and suppression of proliferation of these cells. In addition, mir-663 alters the DNA content and induces phenotypes of mitotic catastrophe in tumor cells. Moreover, the liposome-mediated delivery of mir-663 suppressed the in vivo growth of the BGC823 and SNU5 cells. Western blot analyses performed after the introduction of mir-663 revealed upregulation of cyclin B following transfection with mir-663. Our results provide evidence that downregulation of mir-663 in tumor cells may contribute to aberrant cell hyperplasia, leading to the development of gastric cancer. Therefore, mir-663 might function as a potent suppressor of tumor growth.
Introduction
The known classes of genes that function as tumor suppressors and oncogenes have recently been expanded to include the microRNA (miRNA) family of regulatory molecules. miRNAs are a class of conserved non-coding 20-22-nt small RNAs that regulate gene expression by binding to mRNA; this binding leads to mRNA degradation or inhibition (1) . miRNAs have been implicated in diverse processes such as cellular differentiation, cell cycle control, and apoptosis (2) (3) (4) (5) (6) . The analysis of miRNA expression profiles in cancer cells has revealed essentially ubiquitous dysregulation of these molecules in a wide variety of tumors (1, (7) (8) (9) (10) . It is clear that many of these changes in expression are not simply a secondary consequence of the transformation process. Loss of function of specific miRNAs appears to be a key event in the genesis of diverse cancers. The loss of function of miR-15a and miR-16-1 due to genomic deletion is very common in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), multiple myeloma, and prostate cancer (11) . The downregulation of the let-7 family, the gene clusters of at least 4 of which are found in regions frequently deleted in diverse human malignancies, is associated with poor prognosis in lung cancer (2, 12) . Since many classical tumor suppressor genes are inactivated not only by deletion or mutation but also by aberrant hypermethylation, we hypothesized that miRNA genes might be silenced in human tumors by the hypermethylation of CpG islands surrounding them (13, 14) . Mir-663 is located in a hypothetic gene and has a CpG island near the promoter. In a study, aberrant hypermethylation was found in 62% of 71 primary human breast cancer specimens (15) . However, the role of mir-663 in cancer development remains largely unknown.
In this study, we found that mir-663 was downregulated in human gastric cancer cell lines. Transient introduction of mir-663 into the human gastric cancer cell lines BGC823 and SNU5 induces phenotypes of mitotic catastrophe in tumor cells, but not in normal cells. miRNA-based treatment for human tumors has been documented extensively. The tumor suppressor role of mir-34 has been confirmed in vivo with these tumor xenografts via activation of the p53 pathway (16) . The use of locked nucleic acid anti-mir-21 oligonucleotides has been reported to reduce the growth of U87 glioblastoma xenograft by >70% (17) . In the present study, mir-663 significantly suppressed the in vivo growth of BGC823 and SNU5 cells when introduced into the cells by lipid-mediated gene delivery. There is currently an increased interest in using miRNAs for therapeutic benefit.
Materials and methods
Cell culture conditions and transfection. The gastric epithelial cell line GES1 (a gift from Dr Yang Ke, Peking The expression was quantified using the PCR primer of U6 (F: 5'-GCTTCGGCAGCACATATACTAAAAT-3', R: 5'-CGCTTCACGAATTTGCGTGTCAT-3') and the PCR primer of mir-663 (F: 5'-GTGCGTGTCGTGGAG TCG-3', R: 5'-TTTAGGCGGGGCG-3'). The expression was normalized using endogenous U6 as the control. The data were analyzed using the SDS relative quantification software (Applied Biosystems Inc.).
Cell proliferation assay. The cells were trypsinized and then resuspended in complete medium and seeded onto 96-well plates at 2x10 3 cells per well. The cells were counted by using the cholecystokinin octapeptide (CCK-8) on the indicated days according to the manufacturer's instructions; the optical density (OD) was 450 nm. All experiments were performed in triplicate and repeated twice.
Cell cycle analysis. For cell cycle analysis, cell suspensions were washed twice in phosphate-buffered saline (PBS) and fixed in cold 70% ethanol for 4 h. The fixed cells were then washed with PBS, incubated with 100 mg/ml Rnase A for 30 min at room temperature, stained with propidium iodide (PI) (25 mg/ml), and analyzed by flow cytometry.
Determination of mitotic catastrophe index. The cells were harvested for the determination of the mitotic index as described previously (18) . The slides were examined under a microscope; mir-663-treated cells stained with Giemsa were subdivided into 2 types of cells according to their nuclear morphology. Only cells with distinct interphase nuclei, metaphase spreads, or the appearance of mitotic catastrophe were counted. Giant cells containing multiple evenly stained nuclei and/or small nuclear fragments (micronuclei) were considered to have an 'abnormal' nucleus. At least 1000 cells were counted on each slide for the determination of the mitotic catastrophe index. Three independent experiments were analyzed (19) .
Chromosome analysis. After 72 h of culture incubation, 0.25 ml colchicine (10 μg/ml) was added to each 15-ml tube. The tubes were inverted several times to ensure proper mixing. Next, the cultures were returned to the incubator at 37˚C for 20 min. The cells were resuspended by inverting the tubes, and then the tubes were centrifuged for 8 min at 1200 rpm. The supernatant was aspirated with a sterile Pasteur pipette connected to a vacuum apparatus. The cells were resuspended by using a bulbed 9 inch Pasteur pipette. A warm hypotonic KCl solution (1-3 ml) was slowly added to the tubes until a volume of 10 ml of 0.075 M KCl was reached. Air was blown into the suspension with a bulbed pipette after each addition of the KCl solution. Next, the tubes were incubated at 37˚C for 18 min. Freshly prepared cold fixative [1 ml; 1:3 methanol: acetic acid (4˚C)] was added to each tube very slowly (dropwise). The cells were resuspended in the solution. Next, microslides were prepared by dropping the harvested metaphases onto their surfaces, which were previously rinsed with absolute ethanol. These cells were then stained with Giemsa, and the chromosomes were counted under a microscope.
Immunofluorescence. Antibodies to ·-tubulin (clone DM1A) and Cy3-conjugated goat anti-mouse antibodies were purchased from Sigma. Cells were fixed in 2% formaldehyde for 10 min and permeabilized with 0.5% Nonidet P-40 in PBS (·-tubulin). Antibodies to ·-tubulin were used at a 1:100 dilution. The nuclei were stained with 1 mg/ml 4',6-diamidino-2-phenylindole (DAPI), and the cells were analyzed under a Nikon microscope. The nuclear morphology of at least 200 cells in each sample was examined.
Western blotting. For the Western blot analysis, cellular proteins were extracted in 40 mM Tris-HCl (pH 7.4) containing 150 mM NaCl and 1% (v/v) Triton X-100, supplemented with a cocktail of protease inhibitors. Equal amounts of protein were resolved on 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) gels and then transferred to a polyvinylidene fluoride (PVDF) membrane. After blocking with 5% non-fat milk, the membranes were incubated first with the primary antibody (4˚C, overnight), cyclin B (PharMingen), surviving cyclindependent kinase 2 (CDK2) (Santa Cruz), cyclin-dependent kinase 4 (CDK4; Santa Cruz), and ß-actin (Sigma). Next, the membranes were incubated with horseradish peroxidase (HRP)-conjugated sheep anti-rabbit or anti-mouse IgG secondary antibodies (Vector, Burlingame, CA). After washing the membranes, the blots were developed using the Super Enhanced chemiluminescence detection kit (Applygen Technologies Inc., Beijing, China). The protein bands were visualized after exposing the membranes to Kodak X-ray film.
Suppression of tumor growth by liposome-mediated mir-663 transfection.
A volume of 2 μl mir-663 RNA (25 μg/μl; Ribobio Inc.) was incubated with 100 μl of liposome (Engreen Biosystem Co., Ltd., 18668-11) at room temperature for 30 min. After incubation, 102 μl 1X PBS was added until a total volume of 204 μl was reached; thus, the final RNA concentration was 250 μg/ml. This method of RNA-liposome preparation was based on in vitro optimization of BGC823 and SNU5 cells (20) . The tumor-bearing mice were matched by size and divided into groups. The weights of the mice varied by <5% in each treatment cohort. Treatment began 9 days after the injection of the tumor cells, when the mice received 50 μg mir-663 mimic RNA, 50 μg random mimic RNA, or dialysis buffer alone. The therapeutic and control doses were systemically administered into the neoplasm once daily for 10 days; this was followed by a twice-weekly administration until the treatment was completed. The tumor volumes were calculated according to the following formula: volume = length x width 2 /2. After the last treatment, the mice were sacrificed and the tumor weight was measured. The animal experiments were conducted according to the ethics regulations of our institute.
Immunohistochemistry. The paraffin-embedded xenograft tumor sections or sections of human tissue samples were assayed. For immunohistochemical staining, the sections were dewaxed, rehydrated, and then incubated with 3% H 2 O 2 to quench endogenous peroxidase activity. These sections were then blocked, incubated overnight with primary Ki67 and caspase-3 antibodies (Maixin Bio, CA; 15 μg/ml in PBS) and biotinylated secondary antibody; they were then developed and counterstained with hematoxylin. At least 5 areas of each section were examined at a magnification of x200.
Statistical analysis. All data are presented as mean ± SD. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) (SPSS Inc., Chicago, IL).
Student's two-tailed t-test was used to compare the groups. P≤0.05 was considered significant.
Results

The mir-663 gene is expressed in low amounts in gastric cancer cell lines and can change the morphology of these cells.
The promoter of mir-663 is reported to be aberrantly hyper- methylated and might be downregulated in breast cancer cells (15) . The RT-PCR data showed that mir-663 was markedly downregulated in gastric cancer cells unlike in human normal gastric epithelial cells (GES1) or HEK293 and HUVEC cells (Fig. 1A) . We then performed an in vitro gain-of-function analysis by transfecting the mature miRNAs. At 72 h post-transfection, we assessed the level of miRNAs by RT-PCR; the mir-663 mimic RNA was successfully transfected into the cancer cells (Fig. 1B) . The transfection of the mature mir-663 in BGC823 and SNU5 cells caused a distinct change in these cells. The cells transfected with mir-663 became larger and had multiple modalities (Fig. 1C) .
The mir-663 gene suppresses the proliferation of gastric cancer cells and alters their DNA content. The ectopic expression of mir-663 in the BGC823 and SNU5 cell lines resulted in a 5-to 8-fold decrease in cell proliferation ( Fig. 2A) . The analysis of the cell cycle revealed that mir-663 increased the number of BGC823 and SNU5 cells in the G2/M phase (Fig. 2B) . These results indicated that overexpression of mir-663 is sufficient to decrease the in vitro proliferation of gastric cancer cells. DNA content analysis of these cells revealed that the overexpression of mir-663 altered the DNA content of gastric cancer cells. The BGC823 and SNU5 cells transfected with random mimic RNA had DNA content ranging from 2 to 4n, and the mir-663 group had DNA content ranging from 2 to 6 or 8n (Fig. 2C) . mitotic index slides that had several nuclear envelopes, but no obvious chromosomes were present (upper panel of Fig. 3A and B). These structures were neither interphase nuclei nor chromosomal spreads; they were more clearly visible when the cells were stained with DAPI and ·-tubulin (lower panel of Fig. 3A and B) . These structures were present in high numbers only in mir-663-treated cells. We speculated that these were mitotic cells undergoing mitotic arrest, which would explain the 'sub-G2' population indicated in the flow cytometry data. These structures are likely indicators of mitotic catastrophe, which has been shown to occur in cells lacking cell cycle checkpoints such as loss of p53 (21) . The effect of mir-663 induction on mitotic catastrophe was examined. Cells had a significantly higher mitotic catastrophe index in the mir-663 group (abnormal nuclear cells, about 250/1000) than in the parent and random groups (abnormal nuclear cells, about 30/1000) (right panel of Fig. 3A and B) . The chromosome analysis showed that the chromosome number of the BGC823 and SNU5 cells transfected with mir-663 ranged from <40 to >140, and that of cells in the control group was mostly about 46 ( Fig. 3C and D) . These results confirmed that mir-663 can cause mitotic catastrophe in gastric carcinoma cells.
Protein markers of mitotic catastrophe. The cells were transfected with mir-663 and analyzed by Western blot after 72 h for protein markers of mitotic arrest and mitotic catastrophe (Fig. 4A) . The levels of cyclin B were elevated to a greater extent in mir-663-transfected cells than in the control cells. Cyclin B/cell division cycle 2 (CDC2) activity is essential for entering mitosis. In contrast, mitotic exit requires cyclin B/CDC2 suppression, which normally occurs due to the proteasomal degradation of cyclin B after ubiquitination by the anaphase-promoting complex/CDH1 complex (22) (23) (24) . Therefore, cyclin B is very important for the natural cell cycle. Protein of surviving CDK2 and CDK4 had little change with mir-663 (Fig. 4A ).
Gene therapy with mir-663 suppresses the growth of gastric cancer cells in vivo.
The engrafted tumors were treated with mir-663 mimic RNA, which was introduced by liposomemediated gene delivery. The mice were sacrificed 30 days post-injection. The tumor growth was significantly suppressed by the treatment with mir-663 mimic RNA (Fig. 4B) . The tumor burden was reduced by 50% after 30 days of injection. The average tumor volumes decreased significantly with the administration of mir-663 as compared with those that were administered control RNA throughout the entire experimental period of about 30 days (Fig. 4B) . Organs, including the heart, lung, liver, kidney, spleen, and enteron, were subjected to histological analyses. No obvious systemic side effects were observed in the organs of the treated mice. The average mouse weight, excluding the tumor weight, of the treated and control groups were not significantly different when the treatment ended. The tumor tissues treated with mir-663 showed a considerable number of necrotic areas and a significant decrease in Ki67 and increase in caspase-3 immunohistochemistry staining as compared with those treated with control RNA (Fig. 4C) . These results indicate that the introduction of mir-663 suppresses the growth of human gastric cancer cells in an in vivo setting as well.
Discussion
The discovery of the role of miRNAs in various pathological processes has opened up the possibility of using miRNAs in molecular diagnostics and prognostics, particularly in the case of cancer. In our study, mir-663 was identified as a mitotic catastrophe gene in gastric cancer cell lines; this gene almost completely arrested cell proliferation. This miRNA had low expression levels in all gastric cancer cell lines examined by us. Therefore, we concluded that the silencing of mir-663 may be a common event in gastric cancer. The introduction of mir-663 into two gastric cancer cell lines, BGC823 and SNU5, showed strong inhibition of cell proliferation, and a mitotic catastrophe accompanied by the upregulation of cyclin B.
In recent years, the expression 'mitotic catastrophe' has been widely used to describe a form of death of mammalian cells. Roninson attempted to define 'mitotic catastrophe' in morphological terms as a type of cell death resulting from abnormal mitosis, which usually ends in the formation of large cells with multiple micronuclei and decondensed chromatin (26) . The Cdk1/cyclin B complex is essential for mitosis and mitotic catastrophe. Cdk1 interacts with its obligate allosteric activator-cyclin B to form an active heterodimer, the 'mitosis-promoting factor'. The progression from the G2 to M phase is driven by the activation of the Cdk1/ cyclin B complex, whose activity must be sustained from prophase to metaphase (23) . Elevated levels of cyclin B have been found in numerous studies on mitotic catastrophe induced by pharmacological or genetic manipulations. For instance, increase in level of cyclin B was found in human colorectal adenocarcinoma cell lines treated with fluorouracil and 14-3-3s _ / _ colon cancer cells treated with doxorubicin (27) .
For miRNAs whose expression is reduced in the disease state, the reintroduction of the mature miRNAs into the proper tissue could provide a therapeutic benefit by restoring the regulation of target genes, since chemicals, heat, and/or ionizing radiation used as tumor suppressors in the treatment of cancer often induce mitotic catastrophe (21) . We attempted to estimate the effect of mir-663 in cancer treatment. Cationic liposomes have been used successfully for gene transfer in multiple organ systems (28) . The ease of preparation and administration, low toxicity and immunogenicity, as well as the ability to transfer large fragments of insert DNA have resulted in their use as alternative vehicles for gene delivery (29) . Our experiments showed that cationic liposomemediated mir-663 delivery can significantly suppress the growth of gastric cancer cells in vivo. Recently, McCaffrey and coworkers found that sustained, high-level short hairpin RNA (shRNA) expression produced lethal, dose-dependent liver injury (30) . An individual miRNA may post-tanscriptionally regulate over hundreds of different mRNAs, therefore, miRNAs may also have off-target effects and damage normal tissues. Our experiment showed that mir-663 has little effect on the weight of the mice, and their organs had no abnormality. Therefore, introducing mir-663 into tumors might be a promising targeting treatment for cancer. In addition, some miRNAs are reported to be controlled by epigenetic alterations in cancer cells, including DNA methylation and histone modification. Target oncogenes can be regulated by using chromatin-modifying drugs to activate tumor suppressor miRNA; this knowledge can be used to develop novel cancer therapies in the future (31, 32) . Since mir-663 has been reported to be downregulated because of aberrant hypermethylation in cancer, we think that the de-hypermethylation of mir-663 might lead to a powerful anticancer treatment.
The mechanism of mir-663-mediated suppression of gastric cancer cells might be related to the direct modulation of other downstream targets. Although the messenger RNA targets of mir-663 are not known, the identification and validation of such targets could be useful for determining the potential value of the delivery of mir-663 into gastric cancer cells as a cancer-specific therapeutic strategy. Our data suggest that mir-663 may hold significant promise as a novel target in molecular therapy for human gastric cancer.
